Sugi Predict

Sugi Predict / Compounds / SCHEMBL535813

SCHEMBL535813

SCHEMBL535813

[CH2]Oc1cccc(C#N)c1

nearest known ligand 0.46

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ SLC6A2 P23975 2/20 0.46
▸ SLC6A4 P31645 2/20 0.46
▸ SLC6A3 Q01959 1/20 0.46
▸ ENPP2 Q13822 1/20 0.44
▸ MGLL Q99685 5/20 0.43
▸ TSHR P16473 1/20 0.42
▸ TBXAS1 P24557 1/20 0.42
▸ CLK4 Q9HAZ1 1/20 0.41
▸ PDE4A P27815 1/20 0.41
▸ PDE4B Q07343 1/20 0.41
▸ PDE4C Q08493 1/20 0.41
▸ PDE4D Q08499 1/20 0.41
▸ PRSS1 P07477 1/20 0.40
▸ ACR P10323 1/20 0.40
▸ MAP4K4 O95819 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8379001 0.82 PDE4A (0.54) SLC6A2SLC6A4SLC6A3ENPP2TSHR
SCHEMBL15387045 0.80 SLC6A2 (0.47) SLC6A2SLC6A4SLC6A3ENPP2MGLL
SCHEMBL27839327 0.80 PDE4A (0.53) SLC6A2SLC6A4SLC6A3ENPP2TSHR
SCHEMBL897221 0.78 SLC6A2 (0.46) SLC6A2SLC6A4SLC6A3ENPP2MGLL
SCHEMBL10923033 0.78 PDE4A (0.55) SLC6A2SLC6A4SLC6A3ENPP2PDE4A
SCHEMBL27510754 0.78 SLC6A2 (0.50) SLC6A2SLC6A4SLC6A3ENPP2MGLL
SCHEMBL103841 0.78 P4HB (0.55) SLC6A2SLC6A4SLC6A3PDE4APDE4B
SCHEMBL28664278 0.78 SLC6A2 (0.46) SLC6A2SLC6A4SLC6A3ENPP2MGLL
SCHEMBL30083320 0.78 P4HB (0.55) SLC6A2SLC6A4SLC6A3PDE4APDE4B
SCHEMBL19871040 0.78 SLC6A2 (0.46) SLC6A2SLC6A4SLC6A3ENPP2MGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111454188-A Cyclopropylamines as L SD1inhibitors 因赛特公司 2020-07-28 — — CN claimed
CN-110669058-A Tricyclic quinolone carboxylic acid and preparation method thereof 江西农业大学 2020-01-10 — — CN claimed
US-20170342070-A1 CYCLOPROPYLAMINES AS LSD1 INHIBITORS INCYTE CORPORATION 2017-11-30 — — US claimed
EP-3105218-A1 CYCLOPROPYLAMINES AS LSD1 INHIBITORS Incyte Corporation (US) 2016-12-21 — — EP claimed
WO-2015123465-A1 CYCLOPROPYLAMINES AS LSD1 INHIBITORS INCYTE CORPORATION (US) 2015-08-20 — — WO claimed
US-20150225401-A1 CYCLOPROPYLAMINES AS LSD1 INHIBITORS INCYTE CORPORATION (US) 2015-08-13 — — US claimed
EP-1304325-A1 5-(M-CYANOBENZYLAMINO)PYRAZOLE DERIVATIVES Sankyo Company, Limited (JP) 2003-04-23 — — EP claimed
US-11247992-B2 Cyclopropylamines as LSD1 inhibitors INCYTE CORPORATION (US) 2022-02-15 — — US disclosed
EP-3626713-B1 CYCLOPROPYLAMINES FOR USE AS LSD1 INHIBITORS INCYTE CORP (US) 2021-09-29 — — EP disclosed
US-20210032244-A1 CYCLOPROPYLAMINES AS LSD1 INHIBITORS INCYTE CORPORATION 2021-02-04 — — US disclosed
CN-111454188-A Cyclopropylamines as L SD1inhibitors 因赛特公司 2020-07-28 — — CN disclosed
US-10717737-B2 Cyclopropylamines as LSD1 inhibitors INCYTE CORPORATION (US) 2020-07-21 — — US disclosed
EP-3626713-A1 CYCLOPROPYLAMINES AS LSD1 INHIBITORS Incyte Corporation (US) 2020-03-25 — — EP disclosed
US-20050215578-A1 Thiadiazole compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2005-09-29 — — US disclosed
EP-1550661-A1 THIADIAZOLE COMPOUND AND USE THEREOF Sumitomo Chemical Company, Limited (JP) 2005-07-06 — — EP disclosed
WO-2005042542-A1 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 — — WO disclosed
EP-1475374-A1 THIADIAZOLE COMPOUNDS AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2004-11-10 — — EP disclosed
EP-1329160-A2 4-ACYLAMINOPYRAZOLE DERIVATIVES Sankyo Company, Limited (JP) 2003-07-23 — — EP disclosed
EP-1304325-A1 5-(M-CYANOBENZYLAMINO)PYRAZOLE DERIVATIVES Sankyo Company, Limited (JP) 2003-04-23 — — EP disclosed
US-4517197-A ANTIDEPRESSANTS DELALANDE S.A. (FR) 1985-05-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150225401-A1 CYCLOPROPYLAMINES AS LSD1 INHIBITORS KDM1B, KDM1A, KDM2A SLC6A2 2317/4885SLC6A4 2136/4885SLC6A3 2844/4885
US-10717737-B2 Cyclopropylamines as LSD1 inhibitors KDM1B, KDM1A, KDM2A SLC6A2 2317/4885SLC6A4 2136/4885SLC6A3 2844/4885
US-20050215578-A1 Thiadiazole compounds and use thereof C5, C3AR1, TH SLC6A2 3967/4885SLC6A4 3065/4885SLC6A3 1231/4885
US-20170342070-A1 CYCLOPROPYLAMINES AS LSD1 INHIBITORS KDM1B, KDM1A, KDM2A SLC6A2 2317/4885SLC6A4 2136/4885SLC6A3 2844/4885
US-11247992-B2 Cyclopropylamines as LSD1 inhibitors KDM1B, KDM1A, KDM2A SLC6A2 2317/4885SLC6A4 2136/4885SLC6A3 2844/4885
US-20210032244-A1 CYCLOPROPYLAMINES AS LSD1 INHIBITORS KDM1B, KDM1A, KDM2A SLC6A2 2317/4885SLC6A4 2136/4885SLC6A3 2844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.